Market Newsdesk

SAN FRANCISCO, Jan. 06, 2021 (GLOBE NEWSWIRE) — Thistle, a modern, tech-enabled food and nutrition brand that delivers fully-prepared, plant-forward meals to the doorsteps of its customers, today announced it has raised $10.3 million in a Series B financing led by PowerPlant Ventures, with participation from Siddhi Capital, Alumni Ventures Group, and Rich Products Corporation’s venture arm. PowerPlant Ventures also led Thistle’s Series A which closed just 11 months ago in January 2020.

As a leader in the plant-based meal delivery category, Thistle plans to use the latest funding to bring more fresh, ready-to-eat foods to people across the United States through geographic market expansion, including an additional production facility likely on the East Coast. Setting its sights on a bi-coastal footprint in 2021, the brand expansion will make Thistle available to millions of potential new customers that are eager for both healthier and more sustainable meal services.

“Given rapidly shifting consumer preferences and factors like time or money that impact what foods we eat, Thistle is focused on expanding its operations to become the go-to meal solution that is better for you and for the planet. As always, we’ll never sacrifice taste, convenience, or quality,” said Ashwin Cheryian, Co-Founder and CEO of Thistle. “The pandemic has revealed many challenges within the food system and increased awareness of the paramount role that diet plays in an individual’s health. We’re dedicated to making our products accessible to customers, empowering them to take their personal health by the reins and enjoy the ride, one bite at a time. With this funding, we’ll be able to support even more people through scientific, evidence-based principles of nutrition that lead to optimal wellness, enjoyable eating, and a healthier planet.”

Serving over 5 million meals in the last seven years, Thistle continues to take an individual approach when it comes to maintaining an optimal customer experience. As part of this new funding, the brand will use proceeds to launch new customer offerings including a complimentary virtual consultation with their own in-house registered dietitian. This new resource provides customers access to a specialist who can provide guidance on how to achieve their wellness goals via a whole food, delicious, plant-forward diet.

“We are deeply committed to our customers and to ensuring their experience with Thistle is delightful every time,” said Shiri Avnery, Co-Founder and COO of Thistle. “We review every piece of feedback and noticed a trend among Thistlers asking for additional support on how to live a healthier lifestyle. This sparked the inspiration for virtual consultations with Thistle’s registered dietician. We tested the program last fall, and the responses were overwhelmingly positive. We’re excited to be able to officially roll out the program to our customers this month, with the primary goal to further support our customers along each stage of their wellness journey.”

The direct-to-consumer San Francisco-based startup currently delivers tens of thousands of meals on a weekly basis to customers on the West Coast, averaging a 100%+ annual growth rate since launching in 2013. Thistle’s expansion comes as demand for meal delivery and immunity-boosting foods skyrocketed during the COVID-19 pandemic. Since 2019, Thistle has seen its customer base grow +50%, indicating a sustained trend toward healthy and convenient fresh food options available at the push of a button.

“Eating a plant-forward diet is the single most impactful way to reduce your overall environmental footprint, reducing climate change, pollution, resource consumption, and species extinction,” said Dan Gluck, Managing Partner of PowerPlant Ventures. “Consumer demand for plant-based foods is outperforming total food growth today, and this trend is expected to increase over the next decade as more people realize that eating more plants is a critical component to the long-term health of both the planet and our population. We are thrilled to have led this round of funding for Thistle, a company whose mission we fundamentally believe in and know can make the world a better place one meal at a time.”

In the past 12 months, Thistle grew its West Coast presence by expanding its local delivery and shipping to new markets, including Seattle-Tacoma, Portland, and Las Vegas. In addition, Thistle opened a new facility in Vacaville, CA that runs on 100% non-polluting renewable energy from wind and solar. Thistle also made several strategic executive hires in 2020, including a Chief Financial Officer, Chief Product Officer, and Chief Marketing Officer to support the brand’s continued growth.

For more information on Thistle’s mission and its products, please visit www.thistle.co. Join the conversation by following @ThistleCo on Instagram, Facebook, and Twitter.

ABOUT THISTLE:

Since 2013, Thistle has been on a mission to ensure access to a safe and abundant food supply composed of real, whole foods that both improve human health and reduce our environmental footprint. Cofounders Ashwin Cheriyan and Shiri Avnery saw how two generational problems, the declining health of the population and the planet, pointed to a single solution: get everyone to eat more plants! They set out to develop delicious, plant-forward products as part of a convenient service to allow the modern consumer to  invest in their health and that of the planet. Since 2015, Thistle has delivered 5.5 million meals, built a team of 500+ team members and expanded its offerings to the entire West Coast. Learn more about Thistle’s mission at Thistle.co or view Thistle’s media resources.

ABOUT POWER PLANT VENTURES:

PowerPlant Ventures is a venture capital firm specializing in funding and advancing companies delivering better-for-you food in more sustainable and ethical ways. PPV provides capital, strategic guidance and operating expertise to visionary entrepreneurs leading disruptive plant-based brands including Beyond Meat, Thrive Market, Ripple Foods, Rebbl, Oh My Green, Square Roots, Beanfields, Veggie Grill, Nutriati, Your Super and Vive Organic.

THISTLE MEDIA CONTACT:

Catherine McNally
[email protected]
[email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/41c3c80c-d102-451e-b8ff-cb8f91d95d8d

HERZLIYA, Israel, Jan. 06, 2021 (GLOBE NEWSWIRE) — PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced the appointment of Rita Keynan as Vice President of Pharmaceutical Operations.

Mrs. Keynan brings over 25 years of managerial experience in the pharmaceutical industry. Mrs. Keynan has been responsible for drug development from early phase trials through NDA filings, including managing all chemistry, manufacturing and control (CMC) activities supporting product development, clinical supplies, scale-up, regulatory submissions and commercial manufacturing. Prior to joining PainReform, Mrs. Keynan served as Executive Director of Drug Development at VYNE Therapeutics Ltd., formerly Foamix Pharmaceuticals, where she managed the drug development department that included a team of nearly a dozen employees in Israel, as well as a contract manufacturing organization (CMO) team in Europe. Additionally, Mrs. Keynan collaborated with functional areas including regulatory, clinical, and quality to ensure successful execution of drug development activities to meet project and company goals. Previously, Mrs. Keynan served as CMC Director, Head of CMC/Innovative Research and Development, and Project Manager at Foamix Pharmaceuticals Ltd., a clinical stage special pharmaceutical company. Mrs. Keynan is the co-inventor of over two dozen patents. Mrs. Keynan holds a B.Sc. in Chemistry and a M.Sc. in Pharm from the Hebrew University in Israel.

Ilan Hadar, Chief Executive Officer of PainReform, commented, “I am pleased to welcome Rita as Vice President of Pharmaceutical Operations. Rita brings extensive knowledge and expertise through all stages of drug development and manufacturing, as well as supporting clinical trials and commercial activities. We believe Rita will be an important addition to the team as we prepare to commence our Phase 3 pivotal trials for PRF-110.”

About PainReform

PainReform is a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics. PRF-110, the Company’s lead product, is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed prior to closure to provide localized and extended post-operative analgesia. The Company’s proprietary extended-release drug-delivery system is designed to provide an extended period of post-surgical pain relief without the need for repeated dose administration while reducing the potential need for the use of opiates.

Notice Regarding Forward-Looking Statements

This press release contains forward looking statements about our expectations, beliefs and intentions. Forward-looking statements can be identified by the use of forward-looking words such as “believe”, “expect”, “intend”, “plan”, “may”, “should”, “could”, “might”, “seek”, “target”, “will”, “project”, “forecast”, “continue” or “anticipate” or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. These forward-looking statements are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of our control. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward- looking statements, including, but not limited to, the following: the outcomes of preclinical studies, clinical trials and other research regarding PRF-110 and future product candidates, the commercialization and pricing of our product candidates, our competitors’ development, marketing and sale of products that compete with our products our expectations regarding future growth, including our ability to develop an active trading market for our ordinary shares and whether the market price of our ordinary shares is volatile and our expectations regarding the maintenance of our foreign private issuer status and emerging growth company status. More detailed information about the risks and uncertainties affecting us is contained under the heading “Risk Factors” included in the Company’s recent prospectus included in the registration statement, in the form last filed with the SEC and in other filings that we have made and may make with the Securities and Exchange Commission in the future.

Contact:

Crescendo Communications, LLC
Tel: 212-671-1021
Email: [email protected]

Ilan Hadar
Chief Executive Officer
PainReform Ltd.
Tel: +972-54-5331725
Email: [email protected]

ALHAMBRA, CA, Jan. 06, 2021 (GLOBE NEWSWIRE) — EMCORE Corporation (Nasdaq: EMKR), a leading provider of advanced mixed-signal products that serve the aerospace & defense and broadband communications markets, announced today that it is now shipping its Optiva OTS-1LNG Next-Gen L-Band fiber optic links featuring extended bandwidth for native S- and C-Band from 50 MHz to 6 GHz. These cost-effective transmitter and receiver modules for the Optiva Platform are ideal for satellite antenna signal transport and interfacility link applications.

Optiva Next-Gen L-Band fiber optic transmitter (Tx) and receiver (Rx) pairs are a cost-efficient design using EMCORE’s latest high-speed, uncooled DFB (Distributed Feedback) laser technology. With capability up to 6 GHz covering S- and C-Band, they enable customers to future-proof their systems with better performance at a lower cost than competing alternatives. The native C-Band coverage also provides customers with the optimal solution for 5G C-Band interference.

The Optiva Platform enables long-distance fiber optic links over 100 km with 1/10th the size and weight of coaxial cable. Fiber is much less expensive than coaxial cable over any reasonable distance and the ability to keep the signal in the native satellite frequency reduces signal errors caused by up-and-down-conversion. Fiber also provides greater immunity from EMI (Electromagnetic Interference), hum, and distortion of the signal.

“Our Optiva Next-Gen L-Band fiber optic links present a very high-value proposition to our customers with the extended bandwidth capability to native S- and C-Band providing a major improvement in performance at a lower cost than our previous generation,” said David Wojciechowski, Vice President and General Manager of Defense Optoelectronics for EMCORE. “Our latest Optiva products have a simplified communications architecture resulting in reduced network complexity with lower maintenance cost and increased overall up-time compared to currently available solutions.”

Optiva OTS-1LNG modules feature robust API (Application Programmable Interface) design, 30 dB Tx and Rx adjustable gain range, SmartGain for enhanced AGC (Automatic Gain Control) performance, peak optimizer for quick and easy setup, and RF (Radio Frequency) power monitoring via the front panel and SNMP. They feature DWDM operation that increases transport capacity without increasing fiber count, and when housed in the same Optiva chassis with other Optiva cards, enable a full redundancy system in a single chassis.

For more information on EMCORE’s Next-Gen L-Band fiber optic links and the complete line of Defense Optoelectronics products, email [email protected] or visit us at www.emcore.com/satcom.

About EMCORE

EMCORE Corporation is a leading provider of advanced mixed-signal products that serve the aerospace & defense and broadband communications markets. Our best-in-class components and systems support a broad array of applications including navigation and inertial sensing, defense optoelectronics, broadband transport, 5G wireless infrastructure, optical sensing, and cloud data centers. We leverage industry-leading Quartz MEMS, Lithium Niobate and Indium Phosphide chip-level technology to deliver state-of-the-art component and system-level products across our end-market applications. EMCORE has vertically-integrated manufacturing capability at its wafer fabrication facility in Alhambra, CA, and Quartz MEMS manufacturing facility in Concord, CA. Our manufacturing facilities maintain ISO 9001 quality management certification, and we are AS9100 aerospace quality certified at our facility in Concord. For further information about EMCORE, please visit http://www.emcore.com.

Forward-looking statements:

The information provided herein may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include statements regarding EMCORE’s plans, strategies, business prospects, growth opportunities, changes, and trends in our business and expansion into new markets. These forward-looking statements are based on management’s current expectations, estimates, forecasts, and projections about EMCORE and are subject to risks and uncertainties that could cause actual results and events to differ materially from those stated in the forward-looking statements, including without limitation, the following: (a) uncertainties regarding the effects of the COVID-19 pandemic and the impact of measures intended to reduce its spread on our business and operations, which is evolving and beyond our control; (b) the rapidly evolving markets for EMCORE’s products and uncertainty regarding the development of these markets; (c) EMCORE’s historical dependence on sales to a limited number of customers and fluctuations in the mix of products and customers in any period; (d) delays and other difficulties in commercializing new products; (e) the failure of new products: (i) to perform as expected without material defects, (ii) to be manufactured at acceptable volumes, yields, and cost, (iii) to be qualified and accepted by our customers, and (iv) to successfully compete with products offered by our competitors; (f) uncertainties concerning the availability and cost of commodity materials and specialized product components that we do not make internally; (g) actions by competitors; and (h) other risks and uncertainties discussed under Item 1A – Risk Factors in our Annual Report on Form 10-K for the fiscal year ended September 30, 2020, as updated by our subsequent periodic reports. Forward-looking statements contained in this press release are made only as of the date hereof, and EMCORE undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:

EMCORE Corporation

David Wojciechowski
Vice President and General Manager, Defense Optoelectronics
(626) 293-3715
[email protected]

Investor

Tom Minichiello
Chief Financial Officer
(626) 293-3400
[email protected] 

Media

Joel Counter
Director, Corporate & Marketing Communications
(626) 999-7017
[email protected]

IRVINE, Calif., Jan. 06, 2021 (GLOBE NEWSWIRE) — Syntiant Corp., a deep learning chip technology company advancing AI pervasiveness in edge devices, today announced the availability of its Syntiant^® NDP120™ Neural Decision Processor™ (NDP), the latest generation of special purpose chips for audio and sensor processing for always-on applications in battery-powered devices.

The NDP120 applies neural processing to run multiple applications simultaneously with minimal battery power consumption, including echo-cancellation, beamforming, noise suppression, speech enhancement, speaker identification, keyword spotting, multiple wake words, event detection, and local commands recognition.

“The NDP120 is the first of a family of semiconductors using our next generation Syntiant Core 2 tensor processor platform that brings performance levels previously found in plugged-in devices to a power level suitable to run on batteries,” said Kurt Busch, CEO of Syntiant. “We took years of real world, low-power edge deep learning experience to develop this architecture into a scalable design optimized to bring neural processing to power constrained deployments.”

“Syntiant’s innovation around powerful, cost-effective, and yet power-efficient embedded silicon systems that bring machine learning capabilities right to the edge has been fascinating,” said Arun Rajasekaran, head of technology strategy, wearables and sensors at Poly, a global communications company. “By optimizing its silicon for its deep learning models, Syntiant is making neural processing the pervasive technology to interface between people and machines.”

Syntiant’s NDP120 brings always-on neural processing to all types of consumer products, including mobile phones, earbuds, wearables, smart speakers, laptops, smart home applications and security devices. Ideal for use cases where audio filtering and echo cancelation are required for far-field speech processing, the NDP120 packages the Syntiant Core 2™, a highly flexible, ultra-low-power deep neural network inference engine, with a highly configurable audio front-end interface. The NDP120 also supports multi-modal sensor fusion, including sensors for infrared detection, multi-axis acceleration, tilt, magnetic field, and pressure.

“BraveHeart stands apart in the world of medical sensor applications because we have included Syntiant’s ultra-low-power chip architecture in our design,” said Stuart MacEachern, co-founder, VP of hardware engineering at BraveHeart Wireless Inc., a leading innovator in clinical-quality biometric wearables. “BraveHeart’s applications and partners benefit from this powerful AI edge computing. We are able to offer greater functionality in our devices and be free from the cloud during processing which improves user privacy and security. The NDP120 delivers powerful processing at under one milliwatt, which translates to little strain on our battery consumption.”

An Easy-to-Use Powerful Neural Network

The Syntiant Core 2 moves larger neural networks into always-on domains with capacity to generate shared embeddings, run ensembles, and other neural architectures concurrently or in cascades. The Syntiant Core 2 is a tensor processing core built from the ground up to support energy efficient inference without compromising ease of programming. This second generation architecture delivers 25x the tensor throughput of the Syntiant Core 1™ found in the Syntiant^® NDP100™ and Syntiant^® NDP101™ devices that are currently shipping in high volumes.

Graph Native:
The Syntiant Core 2 is built around a highly optimized tensor-based memory and processing system designed to avoid inefficiencies in stored program architectures. Each layer independently controls its parameter, input, and output tensors consistent with graph-based execution, enabling neural designers with full control of multiple concurrent independent networks, or swapping network configurations depending on operating conditions.

Framework Support:
The Syntiant Core 2 training development kit includes tools for running bit-exact simulations directly within high-level modeling languages, such as Tensorflow and Keras. All major frameworks can port to the Syntiant Core 2 runtime, including native support for multiple types of convolutional kernels, kernel striding, kernel dilation, downsampling layers, fully connected layers, pointwise operations, and a variety of activations.

Compression When You Want It:
The evolving practice of neural compression is natively supported by the Syntiant Core 2. Network architectures can mix 1-, 2-, 4-, and 8-bit weights and higher precision bias terms. For the most challenging tasks, the Syntiant Core 2 supports high precision modes, including 16-bit inputs and outputs. Quantize inference when wanted, but not just because the edge processor requires it.

Secret Sauce:
The Syntiant Core 2 supports a variety of task-dependent under the hood optimizations for sparsity and time series that speed up inference and reduce power requirements without extensive post-training network optimization. With design tools supplied by Syntiant, it is possible to explore the complete power, latency, memory, and parameter requirements on the Syntiant Core 2 interactively, and perform large scale hardware-aware hyperparameter searches with the same tools. The Syntiant Core 2 can shorten time-to-product by months or years as compared to more constrained and power-intensive solutions.

“Syntiant’s highly configurable deep neural network provides enormous flexibility for low-power audio applications and feature extraction,” said Clark Peng, vice president, head of product management at MSI, a world leader in gaming. “The NDP120’s programmable DSP combined with its highly accurate inference engine are ideal for creating high performance voice command applications that can run across both traditional and machine learning algorithms.”

Special Purpose Silicon Designed to Run Multiple DNNs

The NDP120 is equipped with an Arm Cortex M0 Processor and a HiFi-3 DSP. The NDP120’s embedded Syntiant Core 2 supports more than 7 million parameters and can process multiple concurrent heterogeneous networks.

Key features of the NDP120:

• Syntiant Core 2 neural processor
• Support for up to 7 audio streams
• I2S/TDM output audio interface for streaming audio output, including post-processed audio
• Embedded user programmable HiFi-3 DSP
• Deeply embedded Arm Cortex M0 microcontroller for device management with 48KB SRAM, dual-timers, and UART functionality
• Stand-alone operation
• Quad SPI target and controller interface
• I2C serial interface for sensor applications and system interface
• Up to 26 GPIO pins
• Flexible clock generation
• Onboard firmware decryption and authentication
• 3.1 mm x 2.5 mm 42-ball WLBGA package (0.4 mm ball pitch)

The Syntiant NDP120 is sampling now and will be shipping in production volumes in summer 2021. Pricing for 10Ku quantities is $6 per unit. For more information about the NDP120, contact [email protected].

About Syntiant

Founded in 2017 and headquartered in Irvine, Calif., Syntiant Corp. is moving artificial intelligence and machine learning from the cloud to edge devices. Syntiant’s advanced chip solutions merge deep learning with semiconductor design to produce ultra-low-power, high performance, deep neural network processors for always-on applications in battery-powered devices, such as smartphones, smart speakers, earbuds, hearing aids and laptops. The company is backed by several of the world’s leading strategic and financial investors including Intel Capital, Microsoft’s M12, Applied Ventures, Robert Bosch Venture Capital, the Amazon Alexa Fund and Atlantic Bridge Capital. Syntiant continues to be recognized as an industry leader, being named to Gartner’s April 2020 Cool Vendors in AI Semiconductors; Fast Company’s prestigious list of the World’s Most Innovative Companies for 2020; The Linley Group’s 2019 Analysts’ Choice Award in the Best Embedded Processor category; as well as a CES^® 2020 Best of Innovation Awards Honoree. More information on the company can be found by visiting www.syntiant.com or by following Syntiant on Twitter @Syntiantcorp.

Contact:

George Medici
PondelWilkinson
310.279.5968
[email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d8d00152-7f62-426d-9748-8433b103fc4d

 

DENVER, Jan. 06, 2021 (GLOBE NEWSWIRE) — Assure Holdings Corp. (the “Company” or “Assure”) (TSXV: IOM; OTCQB: ARHH), a provider of intraoperative neuromonitoring services (“IONM”), announces that further to its news releases on August 13 and 31 and September 8, 2020, Assure has received a commitment letter (the “Commitment Letter”) from Central Bank & Trust, a part of Farmers & Stockmens Bank (“Central Bank”) in respect of the loan agreement dated August 12, 2020, between Assure and Central Bank.

Pursuant to the Commitment Letter, Central Bank will increase the operating line of credit from US$2.5 million to US$4.5 million (the “Operating Line”) and Assure will concurrently repay the existing approximately US$2 million term loan.

“We are pleased with the new proposed terms of the credit facility which accomplish several important objectives including facilitating our expansion as we further enhance our liquidity position with a more flexible balance sheet,” said John A. Farlinger, Assure’s executive chairman and CEO. “These funds along with our recently closed private placement will be deployed to accelerate organic growth, support new initiatives including our emerging telemedicine offering for IONM and finance targeted acquisitions.”

Farlinger added, “We appreciated Central Bank’s flexibility with regards to our recent early final payment associated with the previously announced acquisition of Neuro-Pro Monitoring that resulted in a reduced cost to Assure.”

Farlinger concluded, “Central Bank has been a valuable partner for Assure and we are pleased to expand our relationship.”

The Operating Line will continue to bear interest at a rate of the Wall Street Journal prime rate plus 2.0%, will mature on June 30, 2022 and is repayable, together with interest, on the first calendar day of each month until maturity. The Operating Line is secured by a first-ranking security interest in all of the present and future undertakings, property and assets of the Company and its subsidiaries.

About Assure Holdings

Assure Holdings Corp. is a Colorado-based company that works with neurosurgeons and orthopedic spine surgeons to provide a turnkey suite of services that support intraoperative neuromonitoring activities during invasive surgeries. Assure employs its own staff of technologists and uses its own state-of-the-art monitoring equipment, handles 100% of intraoperative neuromonitoring scheduling and setup, and bills for all technical services provided. Assure Neuromonitoring is recognized as providing the highest level of patient care in the industry and has earned The Joint Commission’s Gold Seal of Approval^®. For more information, visit the company’s website at www.assureneuromonitoring.com.

Forward-Looking Statements

This news release may contain “forward-looking statements” within the meaning of applicable securities laws, including, but not limited to: the Company’s financing plans; the increase to the Operating Line and the repayment of the existing term loan; the effects of the Operating Line; the proposed use of proceeds in connection with the Operating Line; and the Company’s acceleration of organic growth. Forward-looking statements may generally be identified by the use of the words “anticipates,” “expects,” “intends,” “plans,” “should,” “could,” “would,” “may,” “will,” “believes,” “estimates,” “potential,” “target,” or “continue” and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to: the uncertainty surrounding the spread of COVID-19 and the impact it will have on the Company’s operations and economic activity in general; that the Company’s actions taken during the COVID-19 health crisis will be effective; the Company’s ability to services its obligations under the Operating Line; the Company’s ability to accelerate growth; the Company and Central Bank may not enter into the updated loan agreement; the Company may not use the proceeds as anticipated; and the risks and uncertainties discussed in our most recent annual and quarterly reports filed with the Canadian securities regulators and available on the Company’s profile on SEDAR at www.sedar.com, which risks and uncertainties are incorporated herein by reference. Readers are cautioned not to place undue reliance on forward-looking statements. Except as required by law, Assure does not intend, and undertakes no obligation, to update any forward-looking statements to reflect, in particular, new information or future events.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact

Scott Kozak, Investor and Media Relations
Assure Holdings Corp.
1-720-287-3093
[email protected]

Los Angeles, CA, Jan. 06, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — On November 25, 2019, US Nuclear Corp. (OTC: UCLE) closed on its Securities Purchase Agreement with YA II PN, Ltd., as disclosed on Form 8-K.  The Convertible Debenture given by the company in the amount of $500,000 was fully converted on December 30, 2020, and is now deemed closed and flat.  YA II PN, Ltd. was issued a warrant for the purchase of common stock under the Stock Purchase Agreement, and these warrants are still outstanding with an outside termination date of November 25, 2022.

“The Securities Purchase Agreement was very helpful as it allowed the company to finance and move forward in its long-term program of acquisitions, including the purchase of a 40% interest in Bio-Electronics and Brain Stimulation startup GRAPHETON Inc,” said Robert Goldstein, Chairman and Chief Executive Officer of US Nuclear Corp. 

Mr. Goldstein went on to state, “The full conversion of the debenture into common stock and subsequent stock divestiture clears USN’s debt obligations, while increasing market visibility and improving operational cash flow.”   

Safe Harbor Act

This press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations, estimates and projections and, consequently, you should not rely on these forward looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.

Investors may find additional information regarding US Nuclear Corp. at the SEC website at http://www.sec.gov, or the company’s website at www.usnuclearcorp.com

CONTACT:

US Nuclear Corp. (OTCBB: UCLE)

Robert I. Goldstein, President, CEO, and Chairman

Rachel Boulds, Chief Financial Officer

(818) 883 7043

Email: [email protected]

FREDERICK, Md., Jan. 06, 2021 (GLOBE NEWSWIRE) — TOMI Environmental Solutions, Inc.^® (“TOMI”) (NASDAQ:TOMZ), a global company specializing in disinfection and decontamination, utilizing its premier Binary Ionization Technology (BIT) platform, today announced that Dr. Halden Shane, Chief Executive Officer, will be presenting at the Needham Virtual Growth Conference on Friday, January 15 at 11:30 AM ET. Dr. Shane will also be available throughout the day for virtual one-on one meetings.

A webcast of the presentation will be available to the public at:

https://wsw.com/webcast/needham103/tomz/2292348

TOMI™ Environmental Solutions, Inc.: Innovating for a safer world

^®
 

TOMI™ Environmental Solutions, Inc. (NASDAQ:TOMZ) is a global decontamination and infection prevention company, providing environmental solutions for indoor surface disinfection through the manufacturing, sales and licensing of its premier Binary Ionization Technology^® (BIT^™) platform. Invented under a defense grant in association with the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense, BIT^™ solution utilizes a low percentage Hydrogen Peroxide as its only active ingredient to produce a fog of ionized Hydrogen Peroxide (iHP^™). Represented by the SteraMist^® brand of products, iHP^™ produces a germ-killing aerosol that works like a visual non-caustic gas.

TOMI products are designed to service a broad spectrum of commercial structures, including, but not limited to, hospitals and medical facilities, cruise ships, office buildings, hotel and motel rooms, schools, restaurants, meat and produce processing facilities, military barracks, police and fire departments, and athletic facilities. TOMI products and services have also been used in single-family homes and multi-unit residences.

TOMI develops training programs and application protocols for its clients and is a member in good standing with The American Biological Safety Association, The American Association of Tissue Banks, Association for Professionals in Infection Control and Epidemiology, Society for Healthcare Epidemiology of America, America Seed Trade Association, and The Restoration Industry Association.

For additional information, please visit http://www.tomimist.com/ or contact us at [email protected].

INVESTOR RELATIONS CONTACT:

John Nesbett/Jennifer Belodeau
IMS Investor Relations
[email protected]